AMENDMENTS TO THE CLAIMS

Please cancel claims 94 and 106 without prejudice.

Please amend claims 95-103 and 105 and add new claim 107.

Listing of Claims:

1-94 (Cancelled)

- 95. (Currently amended): The isolated antibody or binding fragment thereof of claim 104 [[94]], wherein the isolated antibody or binding fragment thereof is a polyclonal antibody.
- 96. (Currently amended): The isolated antibody or binding fragment thereof of claim 104 [[94]], wherein the isolated antibody or binding fragment thereof is a monoclonal antibody.
- 97. (Currently amended): The isolated antibody or binding fragment thereof of claim 104 [[94]], wherein the isolated antibody or binding fragment thereof is a humanized antibody.
- 98. (Currently amended): The isolated antibody or binding fragment thereof of any one of claims 95-97 and 104 [[94-97]], wherein the antibody has an affinity of at least 10⁻⁷ M.

2

- 99. (Currently amended): The isolated antibody or binding fragment thereof of any one of claims <u>95-97 and 104</u> [[94-97]], wherein the antibody has an affinity of at least 10^{-8} M.
- 100. (Currently amended): A hybridoma that produces an antibody according to any one of claims 95-97 and 104 [[94-97]].
- 101. (Currently amended): A method of producing monoclonal antibodies, comprising:
- (a) immunizing an animal with a TGF-beta binding protein or portion thereof, wherein said binding protein is selected from the group consisting of:
- (i) a polypeptide encoded by a polynucleotide that comprises a nucleotide sequence selected from SEQ ID NOs:1, 5, 7, 9, 11, 13, and 15, or a complementary sequence thereto, and
- (ii) a polypeptide that comprises an amino acid sequence selected from SEQ ID NOs: 2, 6, 8, 10, 12, 14, and 16;
 - (b) harvesting spleen cells from said animal;
 - (c) fusing said spleen cells with a myeloma cell line; and
- (d) culturing said fused cells under conditions that allow the production of said antibody.
- 102. (Currently amended): A method for the production of an antibody of any one of claims <u>95-97 and 104</u> [[94-97]] comprising culturing hybridoma cells under conditions that allow the production of said antibody.
- 103. (Currently amended): A method for the production of an antibody, or binding fragment thereof, of any one of claims 95-97 and 104 [[94-97]] comprising:

- (a) providing a recombinant host cell capable of producing said antibody; and
- (b) culturing said cell under conditions that allow the production of said antibody.
- 104. (Previously presented): An isolated antibody or binding fragment thereof which binds to a TGF-beta binding protein, wherein said binding protein is selected from the group consisting of:
- (a) a polypeptide encoded by a polynucleotide that comprises a nucleotide sequence selected from SEQ ID NOs:1, 5, 9, 11, 13, and 15, or a complementary sequence thereto, and
- (b) a polypeptide that comprises an amino acid sequence selected from SEQ ID NOs: 2, 6, 10, 12, 14, and 16.
- 105. (Currently amended): An isolated antibody or binding fragment thereof which binds to a TGF-beta binding protein, wherein said binding protein is selected from the group consisting of:
- (a) a polypeptide encoded by a polynucleotide that comprises a nucleotide sequence selected from SEQ ID NOs:1, 5, 7, 9, 11, 13, and 15, or a complementary sequence thereto; and
- (b) a polypeptide that comprises an amino acid sequence selected from SEQ ID NOs: 2, 6, 8, 10, 12, 14, and 16. [[; and]]
- (c)—a polypeptide encoded by a polynucleotide having at least 90% identity with a full length sequence selected from SEQ-ID NOs:1, 5, 9, 11, 13, and 15, or a complementary sequence thereto.

106. (Cancelled)

- 107. (New): A method for immunizing an animal comprising injecting an animal with a TGF-beta binding protein or portion thereof, wherein said binding protein is selected from the group consisting of:
- (i) a polypeptide encoded by a polynucleotide that comprises a nucleotide sequence selected from SEQ ID NOs:1, 5, 7, 9, 11, 13, and 15, or a complementary sequence thereto, and
- (ii) a polypeptide that comprises an amino acid sequence selected from SEQ ID NOs: 2, 6, 8, 10, 12, 14, and 16.